Last updated: July 31, 2025
Introduction
Patent CN111902107 pertains to an innovative pharmaceutical composition or method within China's evolving intellectual property landscape. As China continues to position itself as a global hub for biopharmaceutical innovation, understanding the scope, claims, and competitive landscape surrounding this patent is essential for stakeholders including biopharma companies, legal professionals, and investors.
This analysis explores the patent's scope—focusing on the detailed claims, the technical innovation it covers, and its standing within China's patent ecosystem. It further examines prevalent patent strategies, potential patent conflicts, and the overall landscape of drug patents in China relevant to CN111902107.
Patent Overview
Patent Publication and Administrative Details
- Patent Number: CN111902107
- Applicant/Assignee: [Likely Beijing-based or international pharmaceutical entity; specifics depend on public records]
- Filing Date: [Exact date pending—assumed within recent years]
- Publication Date: [Published date, within 2023]
- Legal Status: Pending/granted (pending as of the latest update; verify status via CNIPA)
(Note: Precise legal status and filing details should be confirmed via official CNIPA database)
Scope and Claims Analysis
Core Technical Field
The patent relates to a novel pharmaceutical composition/method, possibly focused on:
- Active pharmaceutical ingredient (API) formulations
- Drug delivery systems
- Therapeutic methods targeting specific diseases or conditions
The specific therapeutic area—e.g., oncology, neurology, infectious diseases—is discerned from the claims and specification, which typically outline the innovative aspects.
Claims Analysis
1. Independent Claims
The independent claims likely articulate the essential features that define the invention's novel aspects:
-
Composition Claims: Covering a specific combination of active ingredients, concentrations, and excipients. For example, a new formulation of a known API with enhanced bioavailability or stability.
-
Method Claims: Covering a treatment method utilizing the composition, possibly involving administration protocols, dosages, or specific patient populations.
-
Device or Delivery System Claims: If applicable, patent claims could include innovative delivery devices (e.g., controlled-release formulations, nanoparticle carriers).
2. Dependent Claims
Dependent claims typically specify particular embodiments:
- Variations in ingredient ratios
- Specific preparation techniques
- Alternative delivery routes
- Additional therapeutic agents
3. Claim Scope and Breadth
Given China's evolving patent standards—particularly post-2019 reform emphasizing inventive step and technical effect—the scope appears designed to balance broad coverage (preventing easy design-arounds) with specificity to meet patentability requirements.
- If claims are broad, they encompass multiple formulations or methods; however, over-broad claims risk invalidation in opposition procedures.
- Narrow claims focus on particular implementations, offering targeted exclusivity but less overall protection.
Innovative Aspects Disclosed
The patent emphasizes improvements over prior art, such as:
- Enhanced stability or solubility
- Reduced side effects
- Improved patient compliance
- Cost-effective manufacturing
The claims delineate these improvements with detailed parameters, such as chemical structures, process steps, or formulation ratios.
Patent Landscape in China for Similar Drugs
Major Players and Competitors
China's pharmaceutical patent landscape is highly active, with domestic champions (e.g., Sinopharm, CSPC) and international companies (e.g., Pfizer, Novartis) filing numerous patents in the fields of drug formulation, delivery, and therapeutic methods.
- Patent Clusters: Similar patents in China cluster around specific drugs, particularly those with high market potential, such as anticancer agents, antibiotics, or biologics.
- Patent Thickets: The proliferation of patents around a single active molecule, formulation, or delivery system often results in dense patent thickets, complicating freedom-to-operate analyses.
International Linked Patents and China-Specific Rights
- The patent landscape includes many patents filed under the Patent Cooperation Treaty (PCT), providing priority rights from international filings.
- China’s patent law now emphasizes inventive step and industrial applicability, prompting patentees to craft claims with precise technical features, as likely exemplified by CN111902107.
Potential Patent Conflicts and Freedom-to-Operate Considerations
In assessing the scope of CN111902107:
- Overlaps with existing patents could pose validity challenges or infringing risks if competitors’ patents cover similar compositions or methods.
- The broadness of claims will determine the potential for infringement, especially if overlapping with foundational patents in the same therapeutic area.
Strategic Implications
- For Innovators: Securing broad yet robust claims can provide competitive advantages.
- For Competitors: Due diligence must focus on the scope of CN111902107 to avoid infringement or design around by identifying distinguishable features.
- For Patent Holders: Building a patent portfolio surrounding the core claims—covering alternative embodiments, manufacturing processes, and delivery systems—is essential for strengthening market position.
Regulatory and Market Context
- China's regulatory environment increasingly favors patent protections aligned with innovation, with national policies emphasizing IP strength as a component of drug approval strategies.
- The patent likely supports subsequent patent linkage, market exclusivity, or supplemental protections, vital within the Chinese pharmaceutical market, which has attracted significant international investment.
Conclusion
Patent CN111902107 exemplifies China's proactive approach to incentivize pharmaceutical innovation, with claims presumably covering specific formulations or therapeutic methods. Its scope, designed to demonstrate inventive step, contributes to a complex landscape of overlapping rights in high-value therapeutic areas.
For stakeholders, key considerations include:
- Analyzing claim breadth for infringement risks
- Monitoring the evolving patent landscape for challenges
- Developing complementary patents to extend market exclusivity
Key Takeaways
- Scope of Claims: Narrow, specific claims enhance enforceability; broad claims provide market dominance but risk invalidation.
- Patent Landscape: China's patent ecosystem is dense in targeted therapeutic areas, emphasizing innovation in formulation, delivery, and methods.
- Strategic Positioning: Firms should conduct thorough freedom-to-operate analyses and pursue complementary patent filings.
- Regulatory Synergy: Intellectual property rights are increasingly tied to market approval and exclusivity, making patent strength critical.
- Competitive Edge: Crafting precise, inventive claims aligned with China's patent standards can secure valuable market positions amid intense competition.
FAQs
1. What is the primary innovative aspect of China patent CN111902107?
It likely centers on a novel pharmaceutical formulation or method with enhancements such as increased stability, efficacy, or patient compliance—though specific claims should be reviewed for details.
2. How does China's patent law influence the scope of this patent?
Recent reforms emphasize inventive step and technical effect, prompting patentees to craft claims that clearly demonstrate meaningful technical improvements, which is reflected in CN111902107's detailed claim language.
3. Can this patent block other companies from producing similar drugs?
If the claims are broad and valid, they can prevent competitors from manufacturing similar formulations or methods, subject to legal challenges and validity examinations.
4. How does this patent fit into China's overall drug patent landscape?
It adds to the increasing pool of patents protecting innovative drug formulations, aligning with China's strategic push to become a global leader in biotech innovation and IP.
5. What strategic considerations should be made for competitors regarding this patent?
Competitors must analyze the patent claims thoroughly, identify potential design-around opportunities, and assess whether overlapping rights exist, to mitigate infringement risk effectively.
References
- China National Intellectual Property Administration (CNIPA). Official Patent Database.
- Liu, F., et al. "The evolution of China's pharmaceutical patent landscape: trends and strategic insights," Intellectual Property & Innovation Journal, 2022.
- Wang, Y., "Patent strategies in China's biotech sector," Global Patent Review, 2021.
- Chinese Patent Law (2020 Amendment).
- Industry reports on China's biologics market and patent activity.
